Two Sigma Advisers
BCYC

Two Sigma Advisers’s Bicycle Therapeutics BCYC Stock Holding History

Two Sigma Advisers’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-146,100
Closed -$1.03M – 256
2025
Q4 		$1.03M Sell
146,100
-10,600
-7% -$78.2K ﹤0.01% 1468
2025
Q3 		$1.21M Buy
156,700
+86,500
+123% +$653K ﹤0.01% 1363
2025
Q2 		$488K Buy
+70,200
New +$559K ﹤0.01% 1762
2024
Q4 		– Sell
-11,300
Closed -$256K – 2348
2024
Q3 		$256K Sell
11,300
-19,600
-63% -$452K ﹤0.01% 1977
2024
Q2 		$625K Sell
30,900
-15,700
-34% -$355K ﹤0.01% 1788
2024
Q1 		$1.16M Sell
46,600
-15,607
-25% -$332K ﹤0.01% 1509
2023
Q4 		$1.12M Sell
62,207
-8,493
-12% -$141K ﹤0.01% 1588
2023
Q3 		$1.42M Sell
70,700
-68,700
-49% -$1.57M ﹤0.01% 1373
2023
Q2 		$3.56M Sell
139,400
-48,500
-26% -$1.13M 0.01% 916
2023
Q1 		$4M Buy
187,900
+26,100
+16% +$655K 0.01% 905
2022
Q4 		$4.79M Sell
161,800
-100,900
-38% -$2.71M 0.01% 802
2022
Q3 		$6.11M Sell
262,700
-152,500
-37% -$3.63M 0.02% 658
2022
Q2 		$6.97M Buy
415,200
+286,400
+222% +$6.04M 0.02% 631
2022
Q1 		$5.65M Buy
128,800
+31,600
+33% +$1.48M 0.02% 752
2021
Q4 		$5.92M Buy
97,200
+50,500
+108% +$2.79M 0.01% 694
2021
Q3 		$1.94M Buy
+46,700
New +$1.63M 0.01% 1274

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers's BCYC Position: Q1 2026 in Review

Two Sigma Advisers sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 146,100 shares — an estimated $1.03M sold.

Two Sigma Advisers first reported a position in BCYC in Q3 2021 and held it in 16 quarters. The position peaked at $6.97M in Q2 2022. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Two Sigma Advisers reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 146,100 Bicycle Therapeutics shares in Q1 2026, an estimated $1.03M.
  • Two Sigma Advisers first reported a position in Bicycle Therapeutics in Q3 2021 and held it in 16 quarters.
  • Two Sigma Advisers's Bicycle Therapeutics position peaked at $6.97M in Q2 2022.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.